Accelerate Diagnostics, Inc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Provision for bad debts
Amortization of investment discount
Equity-based compensation expense
Amortization of debt discount and issuance costs
Nonrelated Party
Related Party
Convertible Notes
Total amortization of debt discount and issuance costs
Amortization of debt discount related party
Realized loss on available-for-sale securities
Unrealized (gain) loss on equity investments
Loss (gain) on disposal of property and equipment
Units offering issuance cost
Loss on disposal of property and equipment
Loss on extinguishment of debt
Nonrelated Party
Related Party
Total loss on extinguishment of debt
(Gain) on extinguishment of accounts payable
Loss (gain) on fair value adjustments
Paid-in-kind interest
Inventory write-down
(Increase) decrease in assets:
Deferred compensation plan
Accounts receivable
Inventory
Prepaid expense and other assets
Increase (decrease) in liabilities:
Accounts payable
Accrued liabilities and other
Accrued interest
Nonrelated Party
Related Party
Total accrued interest
Accrued interest from related-party
Deferred revenue and income
Deferred compensation
Net cash used in operating activities
Cash flows from investing activities:
Purchases of equipment
Purchase of marketable securities
Proceeds from sales of marketable securities
Maturities of marketable securities
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Proceeds from issuance of common and preferred stock, net
Proceeds from exercise of options
Proceeds from exercise of options and warrants
Proceeds from issuance of convertible note
Proceeds from debt
Prepayment of forward stock repurchase transaction
Payment of debt issuance costs
Proceeds from issuance of common stocks under employee purchase plan
Units offering issuance cost
Proceeds from issuance of 16.00% Notes
Transaction costs related to debt and equity issuance
Proceeds from issuance of 5.00% Notes
Payment of debt
Payments on finance leases
Transaction costs related to debt
Proceeds from exercise of warrants
Net cash provided by financing activities

Effect of exchange rate on cash
Increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Non-cash investing activities:
Net transfer of instruments from inventory to property and equipment, net
Non-cash financing activities:
Exchange of 2.50% Notes and accrued interest for 5.00% Notes
Fair value of common stock warrant issued in connection with the exchange transaction
Debt premium on issuance of 5.00% Notes
Derivative liability associated with the bifurcated conversion option
Reclassification of bifurcated conversion option to contributed capital
Capital contribution from the exchange of secured note and accrued interest through the issuance of common stock with related party
Extinguishment of derivative liability in connection with extinguishment of 5.00% Notes
Issuance of common stock in connection with extinguishment of 5.00% Notes
Extinguishment of 2.50% Notes through issuance of common stock
2.50% Notes extinguished in connection with exchange transaction
Right-of-use assets obtained in exchange for finance lease obligations
Supplemental cash flow information:
Interest paid
Income taxes paid, net of refunds

Comments